Compound ID | 91
Synonym(s): Zevtera
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against/Indicated for treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults, excluding ventilator-associated pneumonia (VAP) |
| Description: | A cephalosporin |
| Institute where first reported: | Basilea Pharmaceutica, Switzerland |
| Year first mentioned: | 2002 |
| Highest development stage: | Approved by FDA in 2024 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/135413542 |
| Guide to Pharmacology: | ceftobiprole |
| Citations: |
|
| Patent: | CN103275104B |